NCT02527746View on ClinicalTrials.gov

Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
NeutropeniaBreast Cancer
Interventions
DRUG

F-627

F-627 subcutaneous injection on Day 3 of each cycle for 4 cycles. Dose-escalation method was used.

DRUG

EC regimen

Epirubicin 100 mg/m\^2 (in vein) and Cyclophosphamide 600 mg/m\^2 (in vein) on Day 1 of each cycle for 4 cycles.

Sponsors
All Listed Sponsors
collaborator

Fudan University

OTHER

lead

EVIVE Biotechnology

INDUSTRY